TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Health

    The ONS Podcast

    Where ONS Voices Talk Cancer

    Join oncology nurses on the Oncology Nursing Society’s award-winning podcast as they sit down to discuss the topics important to nursing practice and treating patients with cancer.

    ISSN 2998-2308

    Advertise

    Copyright: © Copyright 2017

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Nov 24, 2023
    Show notes

    "I think the key in effective communication is building trust, because without trust, patients are not likely to engage in their care as effectively, which can influence patient well-being and their overall health outcomes. Building trust is, I think, crucial," Deb Christensen, MSN, APRN, AGCNS-BC, AOCNS®, founder and chief patient officer at the Cancer Help Desk, a nonprofit that provides personalized cancer treatment resources, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about strategies oncology nurses can use when approaching difficult conversations with patients across all populations.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to difficult conversations in cancer care.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Deb Christensen's ONS Voice articles about communication

    • Oncology Nursing Podcast:

      • Episode 14: Having Difficult Conversations in Oncology Practice

      • Episode 208: How to Have Fertility Preservation Conversations With Your Patients

      • Episode 235: Self-Advocacy Skills for Patients

      • Episode 253: The Ethics of Caring for People You Know Personally

    • Clinical Journal of Oncology Nursing articles:

      • Tools for Communication: Novel Infrastructure to Address Patient-Perceived Gaps in Oncology Care

      • Breaking Bad News: An Evidence-Based Review of Communication Models for Oncology Nurses

    • ONS Resources:

      • Palliative Care Communication Strategies

      • Shared Decision Making in Prostate Cancer

    • Journal of Oncology Practice article: Role of Kindness in Cancer Care

    • SPIKES: A Framework for Breaking Bad News to Patients With Cancer

    • Ask-Tell-Ask method

    • City of Hope: The Interprofessional Communication Curriculum

    • Center to Advance Palliative Care

    • Agency for Healthcare Research and Quality's Health Literacy Universal Precautions

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "Patients tend to be less anxious when they have a trusting relationship with their providers, with their oncology team on a whole, and they tend to follow through better on their treatment plan because they trust what you're saying. It's not easy to establish a trusting relationship when you first meet someone. But what I found in my practice is that anticipating their needs and really listening to their story has made a world of difference in establishing that trusting relationship—and admitting if I don't know the answer to something or if perhaps I've gotten something wrong." TS 2:32

    "Intellectual empathy asks you to imagine yourself in that person's place. And we've all had challenging experiences; we just don't get through life without them. And as a result, we can generally think of a time when we might have been in a similar situation, maybe not exactly the same, but a similar situation, and garner that empathy for the patient and, importantly, for the caregiver, too. Because we genuinely, genuinely want to understand somebody. Intellectual empathy really comes from listening carefully to what's being said and what's not being said, analyzing different people's perspective, knowing your own bias, and asking open-ended questions." TS 4:41

    "I think that the first thing that an oncology nurse needs to do is recognize that patients have their own autonomy to make their own decisions and not go into a conversation expecting a specific outcome. So going in with the intention to do your best, but also be open to what the patient wants to do." TS 8:30

    "Our biggest foe in all of this communication, these communication strategies, really is time. We just do not have the amount of time. I mean, we love the luxury of time to be able to sit and really get into these kind of deeper conversations with people, but we may only have 30 minutes. We may only have 15. So, how do we do that? That is still a question that's out there that there's a lot of investigating. Are there techniques that can help? And there are." TS 13:47

    "All of these points in the continuum have one thing in common, and that's uncertainty. That's really a whirlpool—uncertainty—for people. One of the communication strategies that I've used with people is letting them know that this is a very common emotion to experience—a sense of loss of control, uncertainty—and that in my experience, that people generally, once they have a plan, the anxiety settles. So, giving them kind of a guidepost, hope in the future, that the anxiety will settle. Because I would say 98% of the time it does, once people gain a sense of control, because they have a plan of action to move forward." TS 16:10

    "The setting is really, really important, especially when you're having these challenging conversations. Always checking for understanding: What is that perception? What is the patient perceiving? What is the caregiver family perceiving? Are they understanding you correctly? And being respectful of what people want to know, because sometimes they don't want to know specific things." TS 21:57

    "Oncology nurses need to be aware of their own biases and their own emotional state when they're going into these emotional conversations, these difficult conversations they really need to be in. You might not always be the right one for the conversation. I think that's an important thing to note too, and be able to admit that you may have had a personal life experience that just is not going to allow you to get around a bias or an emotional reaction to the conversation, and so you might not be the right one." TS 23:11

    "I've always felt like if you can help someone find joy and peace in the moment, then that moment was made better. Life is a series of moments. That's kind of how I get through that piece of it." TS 26:20


    Episode 286: Pharmacology 101: Alkylating Agents Nov 17, 2023
    Show notes

    "When I meet with patients, I try and remind them, 'Yes, you do have these side effects that can happen' and make sure that they're informed, but also try and reassure them that not everyone gets it as severe as maybe the movies and TV shows portray," Dane Fritzsche, PharmD, BCOP, informatics pharmacist from the Fred Hutchinson Cancer Center at the University of Washington Medicine in Seattle, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what oncology nurses need to know about alkylating agents for patients with cancer. This episode is the first in a series about drug classes, which we'll include a link to in the episode notes.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to alkylating agents.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Oncology Nursing Podcast: Pharmacology 101 series

    • ONS Voice oncology drug reference sheets

    • Clinical Journal of Oncology Nursing article: Chemoprevention: An Overview of Pharmacologic Agents and Nursing Considerations

    • ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition)
    • ONS Huddle Card: Alkylating Agents

    • The Emperor of All Maladies: A Biography of Cancer by Siddhartha Mukherjee

    • ChemoCare drug information

    • Hematology/Oncology Pharmacy Association (HOPA)

    • National Cancer Institute's A to Z List of Cancer Drugs

    • Patient education guides created as a collaboration between ONS, HOPA, NCODA, and the Association of Community Cancer Centers:

      • Oral Chemotherapy Education Sheets

      • IV Cancer Treatment Education Sheets

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "Alkylating agents are a very interesting class of chemotherapy agents, both mechanistically as well as historically. I remember back in pharmacy school learning this was actually the first class of medicines used to treat cancer, and it actually starts way back in World War I with the use of sulfur mustard gas, in kind of a military fashion, and then noticing some of the responses that soldiers as well as civilians who were actually exposed to that. They would develop things like bone marrow suppression, as well as other antitumor effects. Sadly, it's rough to see mustard gas as being the first agent to lead to something so remarkable, because it was a weapon of devastation, but it did lead to some breakthroughs." TS 1:43

    "The first thing that jumps to my mind when thinking about alkylating agents is their toxicities and then their supportive care agents that we use to make sure that we're treating our patients well and making their care optimum. So, when I, as an oncology pharmacist, would look at these orders, I immediately am jumping to, are we giving them appropriate antiemetics? Because a lot of these agents are highly emetogenic or moderately emetogenic by NCCN. A lot of them have other organ toxicities, like are really harsh on the kidneys. Are they getting their pre- and post-hydration? And then also many of these agents are very bone marrow suppressing, meaning they're targeting the red blood cells, they're hitting platelets, they're reducing our ANCs and making patients at higher risk for infection, you know, so do we need growth factor support here? Are the patients—their current labs—are they able to take another dose at this time or do we need to dose reduce or delay therapy because their platelets are just too low now?" TS 09:54

    "Honestly, it's probably one of the most important things is collaborating together to help provide optimal patient care. And to me, kind of the biggest thing that jumps out is just good communication between the various team members. I can't tell you how many times I would learn crucial information either from an infusion nurse chatting with the patient or walking down the hall or giving a call to one of our lovely clinical nurse coordinators here at Fred Hutch. You know, I always wanted to make sure that I go in and have the full picture of where the patient's at, what, if any, challenges there have been with this patient's particular case, just to make sure that I'm up to date about them and able to provide as good of care as I can." TS 14:55

    "Unfortunately, this class of drugs does come with kind of those generic chemotherapy side effects that we think of: hair loss, nausea and vomiting, and bone marrow suppression. That just comes as a function of how these work. These agents are not selective for just cancer. They're more selective for rapidly dividing cells. So, that leaves our normal cells that rapidly divide like our hair, our GI tract, our bone marrow, you know, to get hit by these." TS 17:50

    "The next thing I always drill my residents on, when I'm teaching them how to provide actionable and helpful information about their regimens that they're getting, is kind of like you're saying, outlining those expectations. How do you prevent these side effects? When do these side effects even start to show up? Like, am I going to immediately be nauseous right when the cisplatin gets turned on? Well, maybe, not super common, but it's more common that we'll see it in, you know, at the end, in the next couple of days and within the next 72 hours or going into the nuances between acute versus chronic nausea and things like that. So, it's really trying to empower the patients with information. How do they prevent this? What are we doing to help prevent it? And then when should they call us? When is the stuff that we're preventing didn't help? When should they call us to get more help?" TS 24:04

    "I think that's a misconception that we as healthcare professionals can really help alleviate with our patients, reminding them that, yes, they do carry risks, but we also have a lot of supportive care agents to kind of help minimize that toxicity. And then we have this whole team of professionals behind you to help carry you through the treatment." TS 29:34


    Episode 285: Transarterial Chemoembolization: The Oncology Nurse's Role Nov 10, 2023
    Show notes

    "I think oftentimes people think this is just a radiology procedure that is rather benign. That's really the role of the oncology nurse, just to be [an educator], support, emotional support, and a coach," Lisa Parks, MS, APRN-CNP, ANP-BC, nurse practitioner in hepatobiliary surgery at The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what oncology nurses should know about transarterial chemoembolization administration and their role surrounding that procedure. This episode is part of a series about non-IV chemotherapy administration; the others are linked below.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to transarterial chemoembolization.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Oncology Nursing Podcast episodes about non-IV chemotherapy administration:

      • Episode 271: Intraventricular and Intrathecal Administration: The Oncology Nurse's Role

      • Episode 265: Intravesical Administration: The Oncology Nurse's Role

      • Episode 252: Intraperitoneal Administration: The Oncology Nurse's Role

    • Oncology Nursing Forum articles:

      • Symptom Distress in Patients With Hepatocellular Carcinoma Toward the End of Life

      • Living With Hepatocellular Carcinoma Near the End of Life: Family Caregivers' Perspectives

    • ONS Chapters

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "So, TACE was commonly used to treat liver metastatic cancers, primarily metastatic colon cancer, until research showed that some of these cancers were not responding to TACE. Therefore, it is no longer really used in metastatic colon cancer. TACE is used in hepatocellular cancer. It also was used more than 10 years ago to treat metastatic neuroendocrine cancers. But recent research has showed that neuroendocrine cancers respond to this embolization without the use of chemotherapy. By eliminating chemotherapy, we also eliminate the potential for side effects." TS 3:29

    "TACE, or TAE, is usually completed more than once in the course of a patient's treatment. Depending on the tumor burden of the liver, the procedure can be segmentally completed on a liver lobe, or you can do the procedure on the right lobe and then follow-up treatment in about six weeks in the left lobe." TS 5:45

    "This is something that isn't even really taught in medical school. So it's really important to understand that even though this is a postprocedural side effect, there are certain things that you have to be aware of. So, the most common side effect that you will see is right upper-quadrant pain, and this is very common. And if the left side of the liver has received the therapy, this pain can radiate to the epigastric area and the patient will describe it as chest pain. And when you have the patient point to that area where he's having pain, it's often epigastric and it's just a referred pain, it's not cardiac pain, typically. You can get a EKG and troponin, but those are almost always negative and it's just really part of this embolization syndrome." TS 14:30

    "As far as what the oncology nurse needs to really be aware of pre-TACE or pre-TAE, I just want to emphasize the importance of patient education. The patient and their family need to understand again, it's not a surgery, it's a radiology procedure, and that the patient is going to have abdominal pain and nausea and vomiting that will last for several weeks and that is why they are not kept in the hospital for three weeks until these symptoms dissipate. Oftentimes these symptoms will be present until they get reimaged at the medical oncologist and then it's time for them to come back and maybe get another phase of their procedure that they are supposed to have as part of their treatment plan." TS 17:44

    "I do want to let you know, though, that patients that have a significant spike of their transaminases over 1,000, those patients are of great concern of going into liver failure. So, the nurses need to let the patient know that they will be monitored and kept in the hospital until we start to see a downtrend in those transaminases before they will be discharged." TS 19:48

    "As an oncology nurse and medical oncology, [it's] education, education, education. Also being able to triage these patients on the phone, talking them through how to keep themselves hydrated. . . . So I just think it's really a coaching job of the oncology nurse. A lot of reassurance, a lot of suggestions on how to get through this very uncomfortable difficult procedure." TS 21:16

    "I want it to be clear that if you're doing local regional therapy, TACE or TAE, this is considered a palliative procedure. You are not going to get a cure with this treatment. In this situation, neuroendocrine carcinoma, it's already metastatic if you're treating the liver. And with hepatocellular, again, it's still palliative because you're not doing a surgical resection on this patient. And every TACE experience for every patient, I've had patients that've and I've had six of these procedures, every experience they get is different." TS 28:11

    "When the patient comes back to our floor after having the treatment, it's just very important for those nurses to know the 'abnormal normal,' to know that some of the things that they're seeing, the hypertension, the severe pain, the severe nausea, is actually normal and the provider will work with them to try to come up with a regimen that will make the patient as comfortable as possible." TS 33:22


    Episode 284: How AI Is Influencing Cancer Care and Oncology Nursing Nov 03, 2023
    Show notes

    "We incorporate nurses and clinicians and users for any tool from the very beginning. They say, 'You know, we need help with this.' And then we start ideation: We start understanding the problem, we meet with them, we try to see what is it that they're trying to do, is it feasible given the data we have? We go back, we do some research, feasibility study. We say we think this is something we can predict with decent performance. Now let's do it," Nasim Eftekhari, MS, executive director of applied artificial intelligence (AI) and data science at the City of Hope National Medical Center in Duarte, CA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a discussion about how the use of AI in cancer care affects an oncology nurse's daily work.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The advertising messages in this episode are brought to you by LUNGevity.

    Episode Notes

    • This episode is not eligible for NCPD.
    • Oncology Nursing Podcast:

      • Episode 281: Nursing's Role in AI in Health Care

      • Episode 131: NLM Is Changing Health Care Through the Power of Data

    • ONS Voice articles:

      • New Technology Tools Help Oncology APRNs Improve Patient Outcomes

      • AI Ultrasound Is Nearly 100% Accurate in Detecting Thyroid Cancers

      • Nursing Informaticists Are the Backbone of Technology-Driven Care

      • What ChatGPT Says About Belonging and Oncology Nursing

    • Clinical Journal of Oncology Nursing article: Technology and Humanity

    • Oncology Nursing Forum article: Artificial Intelligence for Oncology Nursing Authors: Potential Utility and Concerns About Large Language Model Chatbots

    • Primers for AI concepts and terminology:

      • Introduction to Artificial Intelligence for Beginners

      • 12 Important Model Evaluation Metrics for Machine Learning Everyone Should Know

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "So, there is a lot of applications of AI in cancer care, so I can't possibly give you an exhaustive list. But the ones that come to my mind, at least the ones that we are actively working on are early detection and diagnosis, treatment planning, predictive modeling for predicting unwanted outcomes, remote monitoring, radiology applications, pathology applications, improving operations and helping the resource allocation, precision medicine, and research. And we also started a year or so incorporating AI and helping with drug discovery." TS 2:13

    "We've been using AI for a very, very long time. Recently, we just hear more about AI, but AI is in our lives, in health care or not, all day, every day. Google Maps, Google search, all of this is enabled by AI, but we may not realize even that we're using it." TS 8:27

    "So, for technical challenges, you have to always consider: Is this model performing in a decent manner for this application? And depending on the use case, that's different. If you're providing a decision support to someone that is impacting patient care, then you have to be very careful about model performance. So, model performance is one technical consideration, then how do you really technically integrate with the EMR system? It's not easy, EMR systems are not usually very open, and that's a whole challenge in itself to be able to read from any EMR system in real time and feed data back into it in real time." TS 10:16

    "For nurses to successfully approach and adopt this work, I think the most important thing is to keep an open mind to really realize that these technologies can, at best, take the mundane part of their work away so they can operate at the top of their license, but what AI does best is to do things that are repetitive and doesn't require a ton of human intelligence. I think that would be very helpful. Just that mindset could make things more collaborative and cooperative, and that's the only way that we can make these successful." TS 12:37

    "What could help is for nurses to learn the basic concepts that are involved in the development and deployment and testing of these models, so that they can really understand the limitations and capabilities and they can take an active part in the development as well. So, it's not like we build something for you and then we're trying to convince you this is good for you. We try to build together. As an AI and computer scientist, I'm always learning the medical language. I try to educate myself about the clinicians' workflows and language, and I think the same needs to happen on the clinician side for us to be able to build tools that really work in their workflows for their everyday life." TS 13:58

    "We incorporate nurses and clinicians and users for any tool that will be developed from the very beginning. So, usually, the need for something, like a predictive model, comes from nurses and doctors. They say, 'You know, we need help with this.' And then we start ideation: We start understanding the problem, we meet with them, we try to see what is it that they're trying to do, and is it feasible given the data we have? We go back, we do some research, feasibility study. We come back and say we think this is something we can predict, you know, with decent performance. Now let's do it." TS 14:30

    "All of our models, even the ones that have been in production for the longest, we're still getting feedback, we're still improving, and we're still retraining models, not only with new data that becomes available but also with the feedback that we get from our users." TS 17:43

    "For example, after going live, we've had less ICU admissions because of sepsis or septic shock, or after going live had less sepsis mortality, which is very reassuring. So that seems like we're doing the right thing, and our model is working, but if you want to put your scientist hat on, you cannot say 100% this is the impact of the model because there is a lot of different workstreams that are trying to improve those same metrics. And unless you do a clinical trial or what we call in industry A/B testing, where you control for everything else and it's only the model intervention that is the variable, you cannot say for 100% that this is the impact of the model. That's why we combine our qualitative metrics that seem to be right in the right direction with the quantitative metrics." TS 22:17

    "I think for the first time, something has come up that can really make a big change in health care. I could not say this before generative AI. AI has always been helpful, but now I think it's the time to see real change. We're still experimenting. It's really new technology. We are experimenting with in-house development as well as third-party tools that we are testing and evaluating. Again, there's a huge potential in reducing manual labor and documentation, note taking, there are implications in billing and finance, data abstraction for research or whatever other purposes that we need them, tumor boards, predictive modeling, clinical trial matching is one big use case in oncology, and finding similar patients—something that we've been aspiring to for a really long time—seems to be very possible now with these technologies." TS 25:30

    "The users also weigh in. So, if you're considering it to improve clinical operations, the people who will be using the tool will have a say in, 'Yes, we think this tool will be helpful.' So, it's not just looking at the technical and cybersecurity and ethical and legal aspects, but also is this something that our users will use because that's the ultimate goal. If they don't use it, it doesn't matter how good the tool is. It won't work." TS 31:13

    "Making it successful is not about the technology, but mostly about people and processes and operational support." TS 33:33

    "Helping people, helping clinicians, nurses to be more free of mundane tasks and be able to interact with patients, do patient care, which is what they should be doing, rather than the things that I know a lot of nurses hate. I think we have a very exciting time ahead of us." TS 38:47


    Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Oct 27, 2023
    Show notes

    "Having a nurse-driven protocol, at my facility we call them clinical practice guidelines, allows for that immediate action and swift intervention for the patient," Maura Price, MSN, RN, AOCNS®, oncology clinical nurse specialist at the Lehigh Valley Topper Cancer Institute in Bethlehem, PA, told Jaime Weimer, manager of oncology nursing practice at ONS, during a discussion about what oncology nurses should know about desensitization strategies.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to desensitization strategies after an infusion-related reaction.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • ONS Voice articles:

      • Nurses Have Immediate Access to Necessary Medications and Supplies With Hypersensitivity Reaction Kits

      • For Oxaliplatin Hypersensitivity Reactions, Prevention Is the Best Strategy, but Here's How to Manage Them

      • Nurse Innovators Develop Processes to Combat Common Oncologic Emergencies

    • Clinical Journal of Oncology Nursing articles:

      • Nursing Care of Patients Undergoing Chemotherapy Desensitization: Part I

      • Nursing Care of Patients Undergoing Chemotherapy Desensitization: Part II

    • ONS courses:

      • Fundamentals of Chemotherapy Immunotherapy Administration

      • Oncologic Emergencies

      • ONS Chemotherapy Huddle Card

    • Reaction grading systems:

      • Brown

      • https://www.brighamandwomens.org/Common Terminology Criteria for Adverse Events (CTCAE)

      • CTCAE Grading for Immune System Disorders

      • Immune Hypersensitivity Reaction Types I–IV (as described by Gell and Coombs)

    • Brigham and Women's Drug Hypersensitivity and Desensitization Center

    • Dr. Castell's Drug Desensitization Video

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "An allergic reaction is kind of a more general term that's used when someone has an allergy, whether that be to a medication, an environmental allergy. But an allergic reaction can really range in symptoms, anywhere from mild to severe. So, if a patient tells me 'I'm allergic to amoxicillin' or 'I had an allergic reaction, when I take this drug,' definitely ask them to elaborate." TS 4:40

    "Your assessment in grading is really going to be based on the symptoms that the patient is experiencing during the reaction. So, just personally knowing the CTCAE grading so well, this really helps us to identify those next steps for the patient. So, if the reaction was mild and more of a grade one or two, then we can consider rechallenging the patient after additional meds we're always giving and intervening at that point. So, the patient may already have taken premeds prior to starting the infusion. And then we're giving rescue meds to help them through this reaction. So we could potentially rechallenge at that point and either continue them but at the same rate that we were using it at or, per the prescribing information, maybe slow the rate down." TS 13:58

    "I always like to use the example of a GYN-onc patient that's receiving either typically taxol carbo for either their diagnosis of ovarian cancer or endometrial cancer. So that taxane-platinum doublet is really the gold standard for these patients. We know that that is standard of care for them to receive that doublet chemotherapy. So, if the patient has a reaction to the carboplatin but is willing to continue receiving the drug if they pursue that desensitization, they're still getting that gold-standard treatment. So alternatively, completely fine for the patient if they would not like to pursue that and they tell you 'I'm scared' or for whatever reason they don't, that's why it's just very important to have these conversations up front and educate the patients on the risk versus benefits of all of their treatment options." TS 16:13

    "A great example that I typically use is that patient again with ovarian cancer that had six cycles of taxol carbo. Maybe they then went on to maintenance PARP inhibitor and then several months or years later, they unfortunately have recurrence. That, like you said, it kind of looking back at their treatment history to say, 'Oh my goodness, this patient already had six doses of the taxol carbo.' So even though it looks like it's fresh taxol carbo—maybe in the treatment plan—they've already been sensitized to that, so as you said, making sure that you're looking back and you know their treatment history." TS 24:54

    "Just remembering that with a desens, this is never a permanent tolerance; it's only temporary. So, making sure that we are closely observing the patient, getting their vital signs, educating them, making sure that they know, 'Hey, you've reacted to this drug previously. We of course want to keep you on this drug. That's why we're going this route with desensitization. So, if you are feeling anything out of the ordinary, you want to let us know right away." Making sure that we have our emergency equipment and medications available and right at the bedside or chair side, making sure that there's no contraindications for the desensitization." TS 27:35

    "I think explaining the rationale behind the desensitization and why we're doing it is really key, explaining to them we want to keep you on this drug that you're currently getting, explaining that whole process. None of us like to go into anything without knowing a plan, so it's even just as simple as giving the patient the plan and explaining the process." TS 30:59

    "I'd say the most common misconception that I hear, or get the question about, is this is once and done. So, definitely not the case, it's not once and done. When we do desensitize, just keeping in mind that is a temporary tolerance to the drug. So every time that the patient is going to receive this drug in the future, that is going to require the desensitization. So definitely get that question from nurses that are unfamiliar with it and then also patients thinking like, 'Oh, I'll be good after I get this one time over a long day, then I'll be okay,' but just reiterating, this is for every single subsequent administration with this medication." TS 33:55

    "It's very scary for patients, and as we said earlier, if they have a friend or a family member with them, it's really a scary time for them. So, reassuring all of them, everyone that's there that day, definitely encouraging them. Another thing that I think gets forgotten is just the financial implications of it. So, if we have a younger patient or even a middle-aged patient that's still working full-time, this is not a short infusion that they were used to prior before they had the reaction. This is a long day. So if they are working full-time, making sure that they understand, 'You are going to need to miss a day of work each time that you get this going forward.' So, I would say some of those psychosocial things are things that are not often discussed, but definitely important to have that conversation with your patient." TS 34:40


    Episode 282: Telehealth-Based Oncology Palliative Care Oct 20, 2023
    Show notes

    "We really need to do our best to reach people who don't have access to palliative care in their communities, and this is an innovative way for us to do that," Carey Ramirez, ANP-C, ACHPN, nurse practitioner and manager of advanced practice and supportive care medicine at the City of Hope National Medical Center in Duarte, CA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a discussion about how telehealth is overcoming barriers and disparities that previously limited patients' access to timely oncology palliative care.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to telehealth-based oncology palliative care.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Oncology Nursing Podcast:

      • Episode 251: Palliative Care Programs for Patients With Cancer

      • Episode 135: ELNEC Has Trained More Than One Million Nurses in End-of-Life Care

      • Episode 41: Advocating for Palliative Care and Hospice Education

    • ONS Voice articles:

      • Bipartisan PCHETA Legislation Reintroduced in U.S. Senate

      • U.S. Senators Introduce Legislation for Earlier Palliative Care

      • Help Your Patients Prepare for the End From the Beginning

      • APRNs Can Lead by Example When Integrating Palliative Care in Practice

    • Clinical Journal of Oncology Nursing articles:

      • Palliative Care: Oncology Nurses' Confidence in Provision to Patients With Cancer

      • Telehealth in Palliative Care: Communication Strategies From the COVID-19 Pandemic

      • Clinical Oncology Nurse Best Practices: Palliative Care and End-of-Life Conversations

      • Integrating Palliative Care in Hematopoietic Stem Cell Transplantation: A Qualitative Study Exploring Patient, Caregiver, and Clinician Perspectives

    • ONS Palliative Care Huddle Card

    • ONS clinical practice resource: Palliative Care Communication Strategies

    • ONS book: Integration of Palliative Care in Chronic Conditions: An Interdisciplinary Approach

    • Center to Advance Palliative Care (CAPC)

    • Hospice and Palliative Nurses Association (HPNA)

    • National Hospice and Palliative Care Organization (NHPCO)

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "If a person is uncertain of their prognosis or if a provider is uncertain of the goals that the patient has for themselves, that might be an appropriate time to consider palliative consultation. These are all important considerations for triggers that might make palliative a possibility for patients in those scenarios. The take-home message, though, is that the sooner that palliative care is involved, the more likely the patient and family are to benefit." TS 2:51

    "From a patient and family perspective, we frequently find that there are misperceptions regarding palliative care. Oftentimes, they'll conflate the word palliative with either hospice or end-of-life care. They unfortunately sometimes believe that they're one and the same. They demonstrate a lack of knowledge regarding the benefits, including the fact that palliative care can and should be provided alongside life-prolonging care." TS 3:53

    "Palliative providers do their best to help patients maintain hope throughout their disease trajectory, regardless of how well or how poorly things are going. I tend to view things in terms of climbing a sand dune: Living with cancer can sometimes feel like you're walking up a sand dune, either at the beach or at the desert, and there will be days where you take two steps forward and you might slide only one step back. There may also be days where you take two steps forward and slide three steps back. And you find, for example, that if you keep trudging toward the top, that because the winds are constantly blowing those dunes, the top you eventually reach might be different than the one you initially set out to reach. And I think that speaks to the changing nature of hope." TS 6:08

    "It's important to ensure that providers are aware of the local services available to them in their respective communities. [And] we often find that from an organizational or a structural barrier perspective, there are lack of access to palliative care in the community. We often find that outpatient programs may not be as robust, or you may find that there is great variation between outpatient programs with regard to quality." TS 10:10

    "We have multiple patient populations who unfortunately do not have equal access to palliative care. They include rural populations, those who come from low socioeconomic backgrounds. We find that male patients and/or patients who are older adults have lower access to palliative care. We find that those who might be either single or live alone, those who might have an immigrant status, those who don't speak English, those who might have certain cancer diagnoses. It may surprise some of you to know that those with hematologic malignancies actually have much lower rates of palliative referral than those with solid tumors." TS 11:23

    "There's a maldistribution of palliative care resources nationwide. We tend to see that many of the resources are in urban areas, and as a result, we find that a great many rural areas are left untouched. I think it's important for us to recognize that these social determinants of health exist. It's important for us to look intentionally at them and whether they affect some of our patient populations and to work together to overcome them." TS 14:03

    "Anecdotally, I've been doing telehealth for about five years and it's been quite well received. It decreases my no-show rates. It improves my ability to monitor patients over time, and it can be carried out safely." TS 16:12

    "It's important to recognize that telehealth can be utilized not only for a planned appointment that might be scheduled to surveil someone every two weeks or every month from a pain and symptom management perspective, it can also be utilized as a same-day possibility. So if, for example, we have a patient who's due to have an MRI tomorrow and their last MRI was stopped in part because they couldn't tolerate it due to pain or symptoms, we might have a primary team reach out to us and ask whether we can see that patient the day prior to their MRI and devise a plan with that patient so that they can tolerate the MRI more easily the next day." TS 22:26

    "Many of our patients no longer have the ability to get to and from their place of worship, and we can sometimes bring their clergy people to them via telehealth video. We also offer psychology services, psychiatry services, child life services, all via telehealth. And I think it's important to recognize that palliative care is actually made up of an interdisciplinary team, including all of the aforementioned specialists who can basically work together to improve the experience of the patient who is living with cancer and being treated for it." TS 26:41

    "Accept the inevitability of ups and downs. Learn from the downs and persevere. The outcomes are definitely worth it." TS 28:11


    Episode 281: Nursing's Role in AI in Health Care Oct 13, 2023
    Show notes

    "I think the horizon, the trends that we are seeing today, are indicating that this technology is just going to explode and be integrated into everything we do in nursing or beyond. Many of the things with nursing are going to change significantly for us, which has already started," Maxim Topaz, PhD, MA, RN, FAAN, Elizabeth Standish Gill Associate Professor of Nursing at the School of Nursing and The Data Science Institute at Columbia University in New York, NY, and senior scientist at VNS Health, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about nursing's contributions and opportunities to shape in AI in health care.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to the nurse's role with AI in health care.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Oncology Nursing Podcast:

      • Episode 131: NLM Is Changing Health Care Through the Power of Data

    • ONS Voice articles:

      • New Technology Tools Help Oncology APRNs Improve Patient Outcomes

      • AI Ultrasound Is Nearly 100% Accurate in Detecting Thyroid Cancers

      • Nursing Informaticists Are the Backbone of Technology-Driven Care

      • What ChatGPT Says About Belonging and Oncology Nursing

      • AI Mammography Cancer Detection Rates Equivalent to Radiologist Readings
    • Clinical Journal of Oncology Nursing article: Technology and Humanity

    • Oncology Nursing Forum article: Artificial Intelligence for Oncology Nursing Authors: Potential Utility and Concerns About Large Language Model Chatbots

    • Topaz's project on natural language processing: NimbleMiner: An Open-Source Nursing-Sensitive Natural Language Processing System Based on Word Embedding

    • Harvard Business Review article: The Power of Natural Language Processing

    • Nursing and Artificial Intelligence Leadership (NAIL) Collaborative

    • ChatGPT

    • Platforms for courses on AI:

      • Coursera

      • eDEX

      • MOOC

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "So, today, I think this technology advances every week. There are updates for this technology, specifically ChatGPT technology, that are not incremental, I think, they're pretty evolutional, though, and are making me excited about this field. I was excited before, but I was very skeptical, actually, before the recent advancements in the last year or so about our ability to get to a place where we would interact with those large language models." TS 10:31

    "My goal right now is to try to see how we use this technology appropriately for nurses in general, including oncology nursing. The use cases that I can see are more multiple, and one thing is generating the summary of your care. If the interaction between you and the patient can be recorded, then some summary can be generated. Now in oncology, there are a lot of things that machine learning in general, including technologies like ChatGPT, can do." TS 13:35

    "When we build machine learning models using the secondary data that kind of captures those biases, then this propagates. So their ability, those machine learning models, they just learn patterns from data. So, they're going to be biased as well as the data that goes in, basically." TS 18:25

    "You need to think about your population. You need to think about your specific setting. You need to think about what are the historic factors that kind of influence what's going on in practice. And, what is your kind of moral compass. And then, you make decisions about how to fix the machine learning algorithm." TS 22:04

    "The field that, today, kind of the name for this field, I think, is changing to AI, right. They used to call this informatics. So, you know, that's kind of traditional name, right, that is what you would search for on those platforms, so like healthcare informatics, right. I have a course on eDEX. This platform that thousands of people from more than fifty countries have taken and learned about informatics." TS 35:33

    "[In terms of nurses] thinking about ethical aspects and thinking about some of the biases that can be embedded in the technology, we're really good at this. I would definitely encourage nurses that are seeing explosion of this technology to think about those trends and not just blindly apply this knowledge in practice, but think about what implications does it have for our patients? So having the patients in mind, having the person in mind, is kind of that central thing. And that's what we're doing every day." TS 42:08


    Episode 280: Create a Culture of Safety: Learning Culture Oct 06, 2023
    Show notes

    "As nurses and healthcare providers, we need to be up to date with the most current evidence-based practices. To achieve and maintain this, we must institute a learning culture. It is critical to promote a learning culture and healthcare institution to keep both patients and nurses safe," Klara Culmone, MSN, RN, OCN®, assistant nurse manager at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health in New York, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what oncology nurses should know about creating a learning culture in the workplace for nurses at all levels, from staff to managers and administrators.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to creating a culture of learning and safety.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Oncology Nursing Podcast:
      • Episode 246: Create a Culture of Safety: Fair and Just Culture
      • Episode 266: Create a Culture of Safety: Reporting Culture
      • Episode 231: Nurses Thrive in a Healthy Work Culture
    • ONS Voice culture of safety topic tag
    • Clinical Journal of Oncology Nursing article: Vaught's Single Story and Health Care's Culture of Safety
    • ONS professional development resources
    • ONS On-Demand™
    • The Joint Commission's 11 Tenets of a Safety Culture

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "There are a few ways to demonstrate to nurses that a healthcare organization values and promotes a learning culture. So, for example, allowing the time off to attend relevant conferences including covering costs such as transportation, registration, et cetera, as we know that these costs can really go up quickly." TS 2:20

    "Allowing time off the unit with the adequate coverage is really critical, and I think that's a challenge that many of us face right now. So, staffing may not always allow for it, but trying to have a plan set in advance can really help ease this challenge. So, some things that we have implemented to minimize staffing impact on the unit would include, perhaps, paying the nurse to attend the class on a day outside of their scheduled shift, so this is especially helpful for remote learning." TS 5:48

    "Nurse leaders are really critical in the development of a positive learning environment. Nurse leaders should conduct the learning needs assessment within their team and then tailor the educational plan based off of the results. And this really, ideally, should be done in collaboration with their nursing professional development specialists. It's important for nurses to share new knowledge with one another." TS 7:59

    "One of the best ways for nursing schools and facilities to collaborate is by hosting student clinical groups. Having nursing students work with nurses allows the nurse to share their knowledge with the future of the nursing workforce. They are teaching a new generation of nurses. I mean, many of us remember the best clinical experiences during our training. And it is always the preceptor nurse who spent the most time teaching and answering our questions that gave us the motivation and drive to continue learning." TS 10:39

    "I would just really encourage all of our fellow nurses to just be open to new learning, open to new ideas, and willing to teach one another, because I think we really do the best when we build one another up, we listen to each other, and we learn from one another." TS 19:20


    Episode 279: Hematopoietic Stem Cell Transplantation for Scleroderma and Other Autoimmune Diseases Sep 29, 2023
    Show notes

    "I think the most amazing thing we see is the softening of the skin, which can occur during the first two weeks of the conditioning regimen. The nurses on the floor see it, and I think it's just a tremendous gratification for them to see the results of something right before your eyes," Tanya Helms, PA-C, from the division of hematological malignancies and cellular therapy at Duke University Medical Center in Durham, NC, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a discussion about what oncology nurses should know about transplantation for patients with non-oncologic conditions such as autoimmune disease, how the transplant process differs for non-oncology indications, and the clinical pearls oncology nurses should consider when caring for patients with autoimmune diseases during the transplantation process.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge related to hematopoietic stem cell transplantation for scleroderma and other autoimmune diseases.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Oncology Nursing Podcast:

      • Episode 173: Oncology Nurses' Role in Stem Cell Transplants for Pediatric Sickle Cell Disease

      • Episode 148: Stem Cell Transplant Nursing in the Home Setting

    • ONS Voice article: What Oncology Nurses Need to Know About Vaccination and Cancer (and other immunocompromised diseases)

    • Clinical Journal of Oncology Nursing article: Early Intervention With Transplantation Recipients to Improve Access to and Knowledge of Palliative Care

    • ONS course: Hematopoietic Stem Cell Transplantation

    • ONS Huddle Card™: Hematopoietic Stem Cell Transplantation

    • National Scleroderma Foundation

    • New England Journal of Medicine article about the SCOT trial: Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

    • Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation

    • Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

    Highlights From Today's Episode

    "The goal of treatment for patients with scleroderma is to reset the immune system, and there are three main components of the regimen used at Duke—that's total body radiation, cyclophosphamide, and ATG. This targets all the areas where the immune effector cells live. We also use CD34 selection, which is a process that separates CD34-positive cells from the stem cell product that's collected prior to transplant, to eliminate the possibility of reinfusing activated immune cells back into the patients." TS 3:18

    "For patients with diffuse scleroderma, you want to offer transplant when they have evidence of significant disease, but they're not so compromised that they can't tolerate or have increased risk of complications from the conditioning regimen. Understanding the patient's rate of disease progression is key when determining to transplant." TS 6:45

    "When a patient is referred, we call the patient, and we talk about how the transplant conditioning regimen works to reset the immune system and stop disease progression. We explain the workup visit and go over an example of the timeline needed to collect the cells, admit to the hospital for conditioning, and the recovery process as an outpatient. We want patients to understand the big picture before they ever come to Duke." TS 7:57

    "Some patients come to us significantly disabled by their scleroderma. They may be in a wheelchair, so they require special vehicles for travel. Patients whose hands are severely involved need assistance with their ADLs [activities of daily living]." TS 11:43

    "There have been three clinical trials that show autologous transplant improves event-free survival and overall survival and has been shown to decrease all-cause mortality. But it does not repair damaged gastrointestinal, pulmonary, or cardiac tissue. Any fibrosis that has happened is permanent." TS 12:22

    "The most amazing thing we see is the softening of the skin, which can occur during the first two weeks of the conditioning regimen. The nurses on the floor see it, and I think it's just a tremendous gratification for them to see the results of something right before your eyes." TS 13:01

    "Social media has been a huge contributor towards patient self-referrals. Patients are telling their stories on Facebook; patients are asking other questions about how to get referred to a transplant center; and patients whose rheumatologists have not referred them will seek out transplant centers to learn more about transplant for scleroderma." TS 13:48

    "For people with hematologic malignancies, it's all about getting that patient to remission and then transplanting them. . . . These patients have experienced chemotherapy and the adverse effects. They know about low blood counts and fatigue and recovery. They know about central lines and transfusions. The scleroderma patients come to transplantation with progressive disease. They've typically not had blood transfusions, but they are now going to receive total body radiation, chemotherapy, and a stem cell transplant over the next six weeks. And it can be overwhelming. . . . Every day is something new for them to process and learn." TS 14:56

    "Patients become pancytopenic, and they are heavily immunosuppressed. They are on steroids during the conditioning regimen to prevent scleroderma flares during conditioning. These patients have a central line so monitoring for infections, such as assessing vital signs for signs and symptoms of infection, and being aware that steroids can mask a fever." TS 16:49


    Episode 278: Cancer Symptom Management Basics: Hepatic Complications Sep 22, 2023
    Show notes

    "I think that as oncology nurses, we need to keep ourselves really educated and up to date with these new therapies, because I honestly feel like we still haven't really seen the long-term effects of this treatment," ONS member Lisa Parks, MS, APRN-CNP, ANP-BC, nurse practitioner in hepatobiliary surgery at The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center in Columbus, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about recognizing hepatic complications and understanding the basics of its symptom management strategies. This episode is part of a series on cancer symptom management basics; the others are linked below.

    You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

    Music Credit: "Fireflies and Stardust" by Kevin MacLeod

    Licensed under Creative Commons by Attribution 3.0

    The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.

    Learning outcome: The learner will report an increase in knowledge in cancer symptom management basics and hepatic complications.

    Episode Notes

    • The NCPD activity for this episode has expired, but you can still earn NCPD through many other ONS Podcast episodes. Find a full list of opportunities.
    • Oncology Nursing Podcast:

      • Episode 269: Cancer Symptom Management Basics: Gastrointestinal Complications

      • Episode 256: Cancer Symptom Management Basics: Hematologic Complications

      • Episode 250: Cancer Symptom Management Basics: Dermatologic Complications

      • Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications

    • ONS Voice article: To Prevent Hepatotoxicity, Monitor Liver Function During Cancer Treatment

    • Clinical Journal of Oncology Nursing articles:

      • Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management

      • Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Related to Hematopoietic Stem Cell Transplantation

      • Use of Hepatic Artery Infusion Pumps in the Treatment of Hepatic Metastases

    • ONS courses:

      • ONS/ONCC Chemotherapy Immunotherapy Certificate Course

      • ONS/ONCC Radiation Therapy Certificate Course

    • ONS books:

      • Cancer Basics (third edition)https://www.ons.org/books/cancer-basics-third-edition

      • Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition)

      • Manual for Radiation Oncology Nursing Practice and Education (fifth edition)

      • Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition)

    • American Gastroenterological Association

    • American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

    To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.

    To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org

    Highlights From Today's Episode

    "There is something called chemotherapy-induced liver injury. What the chemotherapy does is it has a direct hepatotoxic effect on the hepatocytes themselves. If you have preexisting liver disease such as cirrhosis, it can lead to very severe hepatotoxicity because the function of the liver is already compromised by the damage previously done to it." TS 3:47

    "The American Gastroenterological Association published guidelines on the management of HBV reactivation for patients during immunosuppressive treatment, and they basically do recommend any patients with a hep B virus that they receive antiviral prophylaxis to prevent this reactivation from occurring. Also in 2008, the CDC recommended universal HBV screening for all patients before administering chemotherapy. This one you see most commonly in patients who receive chemotherapy for a hematological cancer following hemopoietic stem cell transplantation." TS 14:19

    "One of the most common things that I've encountered in my practice is that there seems to be a thought that once hepatic complications are identified, there is treatment for this, and in these patients, we can't reverse liver injury. Really, what we offer these patients is supportive care. These patients often can decompensate really quickly, and often these patients may require being transferred to the intensive care unit and it's not because there's any intervention that we're going to do. But I think it's very frustrating for nurses to see these severe liver injuries, that are life threatening, and not to be able to do anything about it." TS 19:06


    Previous 1 14 15 16 17 18 44 Next

    Related Podcasts

    The Joe Rogan Experience

    1

    The Joe Rogan Experience Comedy
    Casefile True Crime

    2

    Casefile True Crime Games & Hobbies
    Reply All

    3

    Reply All Games & Hobbies
    Good Life Project

    4

    Good Life Project Education
    Happier with Gretchen Rubin

    5

    Happier with Gretchen Rubin Health
    The Other F Word: Conversations About Failure

    6

    The Other F Word: Conversations About Failure Health
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights